文献速递妇科

以90天死亡率作为高级别浆液性卵巢癌减瘤手术报告参数

Ninety-Day Mortality as a Reporting Parameter for High-Grade Serous Ovarian Cancer Cytoreduction Surgery.
PubMed 文献 · Obstet Gynecol · 2017-01-01

OBJECTIVE: To evaluate the utility of using 90-day as an adjunct to 30-day mortality rates after surgical cytoreduction for serous ovarian cancer and to compare them across hospitals of differing case volumes over time.…

要点

  • 90天死亡率约为30天死亡率的两倍,各医院业务量类别均呈此规律。
  • 以90天替代30天死亡率进行医院排名,57家医院(9.5%)排名发生变化。
  • 超高通量中心与更低30天和90天风险校正死亡率相关。

核心结论

  • 与低业务量中心相比,超高通量中心与显著更低的30天和90天风险校正死亡率相关。
  • 90天死亡率是30天死亡率的两倍,可能是评估卵巢癌患者初始治疗质量的更优指标。

研究设计与样本

  • 回顾性队列研究,使用美国国家癌症数据库2004至2012年间接受减瘤手术的高级别浆液性癌女性。
  • 医院按年手术量分为低业务量(10例或以下)、中等(11-20例)、高(21-30例)和超高通量(31例或以上)。

主要发现

  • 总体30天死亡率为2.1%(95%CI 1.95-2.3),90天死亡率为5.1%(95%CI 4.8-5.4%,P<.001)。
  • 每个医院业务量类别中,90天死亡率约为30天死亡率的两倍。
  • 以90天替代30天死亡率进行医院排名,57家医院(9.5%)排名变化,其中26家变差、31家改善。
  • 控制年龄、种族-民族、收入、Charlson合并症指数、保险状态、医院业务量、居住地至医院距离、是否接受新辅助化疗及诊断年份后,超高通量中心是90天死亡几率更低的独立预测因素(校正OR 0.60,95%CI 0.38-0.96,P=.034),但30天死亡无统计学显著关联(校正OR 0.64,95%CI 0.35-1.18)。

临床怎么用

  • 原文结论认为90天死亡率可能是评估卵巢癌患者初始治疗质量的更优指标。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the utility of using 90-day as an adjunct to 30-day mortality rates after surgical cytoreduction for serous ovarian cancer and to compare them across hospitals of differing case volumes over time. METHODS: We performed a retrospective cohort study using the National Cancer Database of women undergoing cytoreductive surgery for high-grade serous carcinoma between 2004 and 2012. The primary outcome of the study was mortality rate by hospital volume. The secondary outcome was to evaluate the performance of hospital rankings based on 30- and 90-day mortality rates. Hospitals were categorized by cases per year as low volume (10 or fewer), intermediate (11-20), high (21-30), and ultra-high (31 or more). RESULTS: A total of 24,827 women from 602 hospitals were included. Overall 30-day mortality was 2.1% (95% CI 1.95-2.3) compared with 90-day mortality of 5.1% (95% CI 4.8-5.4%, P<.001). For each hospital volume category, the 90-day mortality was approximately double that of the 30-day mortality. Substituting 90-day in place of 30-day mortality for hospital ranking, 57 hospitals (9.5%) changed ranks (26 worsened and 31 improved). Based on the logistic regression model (after controlling for age, race-ethnicity, income, Charlson comorbidity index, insurance status, hospital volume, distance from place of residence to the hospital, receipt of neoadjuvant chemotherapy, and year of diagnosis), care at the ultra-high-volume centers was an independent predictor of lower odds of death at 90 days [adjusted odds ratios (OR) 0.60, 95% CI 0.38-0.96, P=.034] but not at 30 days (adjusted OR 0.64, 95% CI 0.35-1.18). CONCLUSION: Compared with low-volume centers, ultra-high-volume centers are associated with significantly lower 30- and 90-day risk-adjusted mortality. The 90-day mortality rate is double that of the 30-day rate and may be a better metric for assessing the initial quality of care for patients with ovarian cancer.

来源:Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Spencer RJ, Hacker KE, Griggs JJ, et al. Ninety-Day Mortality as a Reporting Parameter for High-Grade Serous Ovarian Cancer Cytoreduction Surgery. Obstet Gynecol. 2017. PMID: 28697111. doi:10.1097/AOG.0000000000002140

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。